Nabilone ( DrugBank: Nabilone )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	4
13	多発性硬化症／視神経脊髄炎	2
127	前頭側頭葉変性症	1

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03773796 (ClinicalTrials.gov)	August 6, 2018	19/7/2018	Nabilone for Non-motor Symptoms in Parkinson's Disease	Nabilonefor Non-motor Symptoms in Parkinson's Disease: An Open-label Study to Evaluate Long-term Saf ...	Parkinson Disease	Drug: Nabilone 0.25 mg	Medical University Innsbruck	NULL	Recruiting	30 Years	100 Years	All	48	Phase 3	Austria
2	EUCTR2017-004253-16-AT (EUCTR)	13/04/2018	27/02/2018	Investigation of the effect of Nabilon in patients suffering from Parkinson´s Disease with non-Motor ...	Nabilonefor non-motor symptoms in Parkinson’s disease: An open-label study to evaluate long-term saf ...	Subject with non-Motor symptoms of Parkinson´s disease MedDRA version: 20.0;Level: PT;Classification ...	Product Name: Nabilone INN or Proposed INN: NABILONE	Medizinische Universität Innsbruck, Universitätsklinik für Neurologie	NULL	Not Recruiting			Female: yes Male: yes	48	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Austria
3	NCT03769896 (ClinicalTrials.gov)	October 3, 2017	6/12/2018	Nabilone for Non-motor Symptoms in Parkinson's Disease	Nabilonefor Non-motor Symptoms in Parkinson's Disease: A Randomized Placebo-controlled, Double-blind ...	Parkinson Disease	Drug: Nabilone 0.25 mg;Drug: Placebo	Medical University Innsbruck	NULL	Completed	30 Years	100 Years	All	48	Phase 2	Austria
4	EUCTR2017-000192-86-AT (EUCTR)	15/09/2017	10/08/2017	Investigation of the effect of Nabilon in patients suffering from Parkinson´s Disease with non-motor ...	Nabilonefor non-motor symptoms in Parkinson´s disease: A Randomized Placebo-controlled, double-blind ...	Subjects with non-motor symptoms of Parkinson´s disease MedDRA version: 20.0;Level: PT;Classificatio ...	Product Name: Nabilone INN or Proposed INN: NABILONE	Medizinische Universität Innsbruck, Universitätsklinik für Neurologie	NULL	Not Recruiting			Female: yes Male: yes	48	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Austria

First Previous1Next Last

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00480181 (ClinicalTrials.gov)	June 2007	28/5/2007	Efficacy and Safety Evaluation of Nabiloneas Adjunctive Therapy to Gabapentin for the Management of ...	A Comparative, Single Center, Randomized, Double-blinded, Parallel, Placebo-controlled Study to Eval ...	Neuropathic Pain;Multiple Sclerosis	Drug: nabilone;Other: placebo	University of Manitoba	Valeant Pharmaceuticals International, Inc.	Completed	18 Years	65 Years	Both	50	Phase 4	Canada
2	NCT00381264 (ClinicalTrials.gov)	September 2006	25/9/2006	Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis ...	A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Pat ...	Multiple Sclerosis	Drug: Cesamet™ (nabilone)	NEMA Research, Inc.	NULL	Completed	18 Years	75 Years	Both	23	Phase 4	United States

First Previous1Next Last

127. 前頭側頭葉変性症

臨床試験数 : 90 / 薬物数 : 87 - (DrugBank : 30) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 88

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05742698 (ClinicalTrials.gov)	June 2023	23/11/2022	Nabilone for Agitation in Frontotemporal Dementia	Double Blind Crossover Clinical Trial of Nabilone for Agitation in Frontotemporal Dementia	Frontotemporal Dementia;Frontotemporal Dementia, Behavioral Variant;Primary Progressive Aphasia	Drug: Nabilone;Drug: Placebo	Simon Ducharme, MD	Alzheimer's Drug Discovery Foundation	Not yet recruiting	18 Years	N/A	All	45	Phase 3	NULL

First Previous1Next Last

先頭へ